This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Dec. 20, 2013





AST Institutional Support Program
  • Are you interested in receiving recognition and increased exposure for your transplant center?
  • Does your center support the future of transplantation and value the educational, networking, and research opportunities that the American Society of Transplantation (AST) provides to its members?
  • Does your center support AST's lobbying of the U.S. Congress and Federal Agencies to secure a more transplant provider friendly environment for patients and physicians?
If the answer to these questions is YES, please consider having your center participate in AST's 2014 Institutional Support Program. With a charitable contribution of $3,000 to support AST's programs of research, professional education, and advocacy, your center will receive:
  • Quarterly acknowledgement in the American Journal of Transplantation on the support recognition page
  • Recognition on the AST website with a link to your center's website
  • One-time use of the AST membership mailing list (mailing piece must be approved)
  • Opportunity to display literature at the AST 2014 Fellows Symposium
  • One time job listing on the AST Career Center
  • Recognition via signage at the AST booth at the 2014 World Transplant Congress
  • Certificate of Recognition
All donations are tax-deductible. Click here for more information about participation in AST's Institutional Support Program, or contact Liz Piegzik, AST Associate Meeting Manager, at or 856-380-6851.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Cancer/PTLD and kidney allocation update webinars in January
Register now and mark your calendar for the following webinars this January, available live and on demand for viewing at your convenience.

    Cancer/PTLD, Part of the Fellows Live Webinar Series
    Tuesday, Jan. 7, 2-3 p.m. EST
    This webinar presented by Dr. John Gill will present case-based studies highlighting the management of transplant candidates and transplant recipients who have either a history of current diagnosis of cancer. This series is designed for fellows in transplantation but is free and available to anyone interested.

    Update on Kidney Allocation
    Tuesday, Jan. 21, 2-3 p.m. EST
    Dr. John Friedewald, will provide an update on the newly approved kidney allocation policy, tips on how to address implementation within your own transplant program, and what this will mean for patients currently on the list and those currently being evaluated. Registration is free for AST members and $25 for non-members.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE

It's time to renew your AST membership!
If you have not already done so, please renew your AST membership today. In order to continue receiving all of the benefits AST membership has to offer through 2014, please login to the website now at to pay your dues. If you have forgotten your login credentials, simply click the "Forgot Password" link to have the information emailed to you. Please contact the AST office at with any questions.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


ASTAGRAF XL™ (tacrolimus extended-release capsules), prophylaxis of organ rejection in adult kidney transplant recipients, receives unique HCPCS Code
Astellas Pharma US, Inc., recently announced that ASTAGRAF XL™ (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction, was assigned a unique, product-specific Healthcare Common Procedure Coding System (HCPCS) Code by the Centers for Medicare and Medicaid Services (CMS) to distinguish it as an extended-release formulation. This action comes one year earlier than expected, and removes the key reimbursement issues associated with providers submitting a miscellaneous J Code for Medicare Part B. It also helps ensure patient access to ASTAGRAF XL will no longer be delayed due to potential concerns over coding and reimbursement. Learn more about ASTAGRAF XL here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

End-stage kidney disease after pediatric nonrenal solid organ transplantation.
Pediatrics (login required)
Adult solid organ transplant (SOT) recipients commonly develop advanced kidney disease; however, the burden of end-stage kidney disease (ESKD) in children after SOT is not well-described. The objectives of this study were to determine the incidence of ESKD after pediatric SOT and the relative risk by SOT type
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Histoplasmosis after solid organ transplantation
Clinical Infectious Diseases (login required)
In order to improve our understanding of risk factors, management, diagnosis and outcomes associated with histoplasmosis after solid organ transplantation (SOT), we report a large series of histoplasmosis occurring after SOT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Featured Advertisers

Diagnose faster, when it matters most.
For nearly 30 years, physicians have trusted Viracor-IBT Laboratories to provide accelerated results, specialized expertise and exceptional service in transplant testing. Learn more at
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.

Rejection is less common in children undergoing liver transplantation for hepatoblastoma
Pediatric Transplantation (login required)
To compare the incidence of acute histologically proven rejection in children who have had a liver transplant for hepatoblastoma with a control group of children transplanted for biliary atresia (EHBA). A retrospective case notes based study was performed.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Study: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Acta Oncologica
Epstein-Barr virus (EBV) plays a major role in the development of post-transplant lymphoproliferative disorder (PTLD), but there is an increasing awareness of EBV-negative PTLD. The clinical presentation of EBV-negative PTLD has not been as well characterized as EBV-positive cases. Further, there is limited knowledge on the clinical importance of diffuse large B-cell lymphoma cell of origin subtype posttransplant.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit

New clinical research network holds great promise for improving treatments for patients
Finding the most effective ways of detecting, treating and preventing disease is essential to medical progress. Such efforts are known as comparative effectiveness research (CER) and help determine what works and what doesn't work in clinical practice. However, the current infrastructure for CER can be slow and expensive, and may not reflect experience in the real world. The Patient-Centered Outcomes Research Institute (PCORI) has approved $93.5 million supporting 29 clinical research data networks that together will form an ambitious new resource known as PCORnet, the National Patient-Centered Clinical Research Network.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Automated image analysis method for detecting and quantifying macrovesicular steatosis in hematoxylin and eosin–stained histology images of human livers
Liver Transplantation (login required)
Large-droplet macrovesicular steatosis (ld-MaS) in more than 30 percent of liver graft hepatocytes is a major risk factor for liver transplantation. An accurate assessment of the ld-MaS percentage is crucial for determining liver graft transplantability, which is currently based on pathologists' evaluations of hematoxylin and eosin (H&E)–stained liver histology specimens, with the predominant criteria being the relative size of the lipid droplets (LDs) and their propensity to displace a hepatocyte's nucleus to the cell periphery. Automated image analysis systems aimed at objectively and reproducibly quantifying ld-MaS do not accurately differentiate large LDs from small-droplet macrovesicular steatosis and do not take into account LD-mediated nuclear displacement; this leads to a poor correlation with pathologists' assessments
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Missed last week's issue? See which articles your colleagues read most.

    AST and ASTS comments on Proposed Rule OAR 836-053-0008 (AST)
Liver transplant therapy given orphan drug status (Healio)
Study: Living donor comorbidities are increasing (Renal & Urology News)
Ureteral complications after hand-assisted laparoscopic living donor nephrectomy (Transplantation)
3-D print of a liver for preoperative planning in living donor liver transplantation (Liver Transplantation)

Don't be left behind. Click here to see what else you missed.

Blood vessels reorganize themselves after full face transplantation
Fox News
As full face transplantation continues to become a more viable option for patients with severe facial disfigurations, doctors have learned more and more about the intricacies of this novel procedure. Now, for the first time ever, researchers have discovered that in the months following the procedure, the blood vessels in the faces of transplant recipients are actually able to reorganize themselves.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Dec. 13, 2013
Dec. 6, 2013
Nov. 27, 2013
Nov. 22, 2013

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063